prognosis remains very poor with a median survival of less thanayear,andthiswarrantstotesttargetedtherapiesinthis disease.Todate,noconsistentdataconcerningABCandantiangiogenicdrugsisavailable,andveryfewconcerningABC andantiEGFR(epidermalgrowthfactorreceptor)drugs.In this issue of OnkOlOgie, Chang and collaborators [7] report 5 cases of patients with ABC and treated with cetuximab combined with modulated fluorouracil, either as first-or as second-linetreatment.All5patientsshoweddiseasecontrol (1CR,3PRand1SD).ActivityofantiEGFRinABCwas previously reported in two cases (PR achieved in first line using gemcitabine + cetuximab [8] ; PR achieved in first line using radiation therapy combined with cetuximab [9] ), and inaseriesof9patientsresistanttogemcitabine+oxaliplatin (1CR,1PRand1SDoutofthe9patients)afteradditionof cetuximabtoGEMOXatprogression [10] .ResultsofaprospectivephaseIIstudyusingGEMOX+cetuximabasfirst-linetreatmentfor30ABCpatientswerereportedduringthe pastASCO2009,withanimpressive63.3%responserateand a12.7monthsmediansurvival [11] .Atthesametime,preliminaryresultsofaFrench-Germanrandomizedstudy(GEMOX withorwithoutcetuximab)havebeenreported,withapromisingincreaseinprogression-freesurvival(PFS)forthecombinedarm [12] .
It is now well demonstrated that efficacy of EGFR antibodiesisrelatedtotumoralK-RASwild-typestatusandnot toEGFRexpressionincoloncancer [13] .Therefore,EGFR antibodies should be restricted to a sub-population of patients.Thismaynotbethecaseinothertypesoftumor,and relationshipsbetweenEGFRantibodiesactivityandK-RAS mutationalstatushavetobefurtherexplored.EGFRoverexpressionisstronglycorrelatedwithtumorprogressioninABC [14] .K-RAStumormutationshavebeenreportedinABC,at various rates depending on the geographic origin of the patientsaswellasontheprimarytumorlocation:reportedmuBiliary tract cancers comprise a large variety of anatomic situations: intrahepatic cholangiocarcinomas, extrahepatic cholangiocarcinomas, adenocarcinomas of the gallbladder and of ampulla of Vater. Even if they have different prognoses,andrequiredifferentsurgicalprocedureswhenresectable, they are often together considered in clinical trials of chemotherapy for advanced disease. Unfortunately, the majorityofpatientspresentswithunresectablediseaseatdiagnosis,andoverallprognosisremainsverypoor.
The use of chemotherapy in advanced biliary cancers (ABC)wasjustifiedbytheGlimeliusstudy [1] ,wherepalliative chemotherapy demonstrated a survival and a quality of lifeadvantageascomparedtobestsupportivecare.Qualityof biliarydrainageremainsakeyprognosticfactor,andmustbe thefirstgoaltoachievebeforestartingchemotherapy.Until recently,ABCwereconsideredasorphandiseases,andalot ofsmallnonrandomizedstudiesbasedonvariousdrugsand combined treatments have been published. A review of the literature (112 trial arms and 2,810 patients) confirmed the valueofseveralnationalguidelines:single-agentantimetabolites(gemcitabineor5fluorouracil)aremoreactivethanany other single drugs, and combined treatments of antimetabolite+platinumsaltaremoreactivethansingleagentsorany othercombinedtreatment [2] ,themorepromisingcombinationsbeinggemcitabine+cisplatinandgemcitabine+oxali-platin [3, 4] .ThiswaslaterconfirmedthisyearbyoneJapaneserandomizedphaseIIstudy [5] andespeciallybyoneUK randomizedphaseIIIstudy [6] ,whichfoundasignificantadvantageintermsofoverallsurvivalforthiscombinationcomparedtogemcitabinealone.ThisUKstudynotonlydefineda newstandardofcare,butalsodemonstratedthatitisnowfeasibletoperformlarge-scalestudiesinABC.
Targeted therapies are now widely used in oncology, and definitivelyrepresentanewstepinthetherapeuticadvances. Despite the definition of a new standard of care in ABC, Onkologie2010;33: [10] [11] TargetedDrugsinBiliaryTractCancer 11 tationsraterangedfrom0to50%inAsianpatients [15, 16] and from 12 to 54% in patients from western countries [11, 17] ;ingallbladder,ampullomaandextrahepaticcholangiocarcinomas,suchmutationsseemtobeabsentorveryinfrequent [18] . Considering the poor prognosis of gallbladder cancers treatedwithconventionalchemotherapy,thesefindingsareto betakenintoaccount.Interestingly,neitherprogression-free survivalnoroverallsurvivalwereaffectedbyK-RASstatusin theGEMOX+cetuximabphaseIIstudy [11] .
Regarding the poor prognosis of ABC despite the recent definitionofastandardofcare,improvementsofresultsare urgently needed. Antiangiogenic drugs deserve to be tested. The use of EGFR inhibitors appears as a promising option. However, this should be done through well conducted prospective clinical trials, with companion biological explorations,inordertobetterunderstandtheoptimalplaceofsuch drugsinABC.
